EMBRACE – Follow-up				Patie	nt ID:				
Embrace No.		Time	72	84	96	108	120		
Day									
Month									
Year									
Physician (initial	s)								
RECTUM/SIGMOID COLON/BOWEL, morbidity scoring CTC v3.0									
with ADL 3: Increase of ≥7 s interfering with Al 4: Life-threatening 5: Death	licated < IV fluids	24hrs; m	oderate ir	icrease ii	n coloston	ny output compared to baseline; not interfering ease in colostomy output compared to baseline;			
2. Flatulence 1: Mild 2: Moderate									
3. Incontinence (a 1: Occasional use 2: Daily use of pac 3: Interfering with	of pads required	n indicated							
<ul> <li>J. Death</li> <li>4. Proctitis <ol> <li>Rectal discomfort, intervention not indicated</li> <li>Symptoms not interfering with ADL; medical interventio</li> <li>Stool incontinence or other symptoms interfering with AI</li> <li>Life-threatening consequences (e.g., perforation)</li> <li>Death</li> </ol></li></ul>					vention ir	ndicated			
5. Bleeding (hemorrhage GI) Anus									
		Rectum							
Sigmoid									
Colon									
Small bowel 1: Mild, intervention (other than iron supplements) not indice 2: Symptomatic and medical intervention or minor cauterizar 3: Transfusion, interventional radiology, endoscopic, or oper 4: Life-threatening consequences; major urgent intervention 5: Death				ervention	indicated	; radiatio	on therapy	(i.e., hemostasis of bleeding site)	
6. Stricture/steno	sis	Anus							
		Rectum							
		Sigmoid							
		Colon all bowel							
1: Asymptomatic 1 2: Symptomatic; a 3: Symptomatic ar operative intervent 4: Life-threatening 5: Death	d dietary	habits, d	iarrhea, o	r GI flui	d loss); iv	fluids, tube feedings, or TPN indicated $\geq$ 24 hrs;			
7. Fistula		Anus							
		Rectum							
		Sigmoid							
Colon									
Small bowel 1: Asymptomatic, radiographic findings only 2: Symptomatic; altered GI function (e.g., altered dietary hal 3: Symptomatic and severely altered GI function (e.g., altere 4: Life-threatening consequences 5: Death 8. Gastro/intestinal other									
Specify category		l		I		1			
Speeny category	•								

Embrace No.		Time	72	84	96	108	120			
BLADDER, morbidity so	coring CTC v	3.0								
9. Urinary frequency/urgency       Image: Constraint of the second										
10. Incontinence, urinary	y .									
1: Occasional (e.g., with coughing, sneezing, etc.), pads not indicated         2: Spontaneous, pads indicated         3: Interfering with ADL; intervention indicated (e.g., clamp, collagen injections)         4: Operative intervention indicated (e.g., cystectomy or permanent urinary diversion)										
<b>11. Cystitis</b> 1: Asymptomatic 2: Frequency with dysuria; m 3: Transfusion; IV pain medi 4: Catastrophic bleeding; maj 5: Death										
12. Bladder spasm         1: Symptomatic, intervention not indicated         2: Symptomatic, antispasmodics indicated         3: Narcotids indicated         4: Major surgical intervention indicated (e.g., cystectomy)										
13. Bleeding (Hemorrhag	ge GU)	Bladder								
		Ureter								
		Urethra								
<ol> <li>Mild, intervention (other than iron supplements) not indicated</li> <li>Symptomatic and medical intervention or minor cauterization indicated</li> <li>Transfusion, interventional radiology, endoscopic, or operative intervention indicated; radiation therapy (i.e., hemostasis of bleeding site)</li> <li>Life-threatening consequences; major urgent intervention indicated</li> <li>Death</li> </ol>										
14. Stenosis/stricture		Bladder								
		Ureter								
		Urethra								
2: Symptomatic but no hydro 3: Symptomatic and altered of	1: Asymptomatic, radiographic or endoscopic findings only 2: Symptomatic but no hydronephrosis, sepsis or renal dysfunction; dilation or endoscopic repair or stent placement indicated 3: Symptomatic and altered organ function (e.g., sepsis or hydronephrosis, or renal dysfunction); operative intervention indicated 4: Life-threatening consequences; organ failure or operative intervention requiring organ resection indicated									
15. Fistula		Bladder								
		Ureter								
		Urethra								
1: Asymptomatic, radiographic findings only 2: Symptomatic; noninvasive intervention indicated 3: Symptomatic interfering with ADL; invasive intervention indicated 4: Life-threatening consequences; operative intervention requiring partial or full organ resection; permanent urinary diversion 5: Death										
16. Bladder other										
Specify category:										
VAGINA, morbidity score	ring CTC v3.	0		1	1		1			
17. Vaginal dryness 1: Mild 2: Interfering with sexual fun	oction: dyspareuni	a: intervention	indicated	1						
•	• •		marcatee							
18. Vaginal stenosis/length										
19. Vaginal mucositis										
<ol> <li>Erythema of the mucosa; minimal symptoms</li> <li>Patchy ulcerations; moderate symptoms or dyspareunia</li> <li>Confluent ulcerations; bleeding with trauma; unable to tolerate vaginal exam, sexual intercourse or tampon placement</li> <li>Tissue necrosis; significant spontaneous bleeding; life-threatening consequences</li> </ol>										
20. Bleeding (hemorrhag										
1: Minimal or microscopic bleeding; intervention not indicated 2: Gross bleeding, medical intervention, or urinary tract irrigation indicated 3: Transfusion, interventional radiology, endoscopic, or operative intervention indicated; radiation therapy (i.e., hemostasis of bleeding site) 4: Life-threatening consequences; major urgent intervention indicated 5: Death										

Embrace No.	Time	72	84	96	108	120			
VAGINA continued, morbidity scoring CTC v3.0									
21. Fistula (Vagina cont.)       Image: Construct of the symptomatic of the symptomatic of the symptomatic on the symptomatic									
22. Vaginal other									
Specify category									
23. Hormonal therapy 0: no 1: oral 2: vaginal 3: oral + vaginal 9: unknown									
24. Regular vaginal dilatation									
0: no 1: yes 9: unknown									
MUSCLE/SOFT TISSUE/BONE, m	orbidity scori	ng CT	C v3.0						
25. Fibrosis	Pelvic left								
<ul> <li>deep connective</li> </ul>	Pelvic right								
1: Increased density, "spongy" feel 2: Increased density with firmness or tethering 3: Increased density with fixation of tissue; operative intervention indicated; interfering with ADL 4: Life-threatening; disabling; loss of limb; interfering with vital organ function 5: Death									
26. Fracture	Pelvic ring								
	Femoral head								
nondisplaced; immobilization indicated 2: Symptomatic but non-displaced; immobili 3: Symptomatic and displaced or open woun 4: Disabling; amputation indicated 5: Death 27. Muscle/soft tissue/bone other	zation indicated			-			iency fracture on MRI, etc.) Symptomatic but		
Specify category:									
LYMPHATICS, morbidity scoring (	CTC v3.0	-		-		-			
<ul> <li>28. Edema: limb</li> <li>1: 5 – 10% inter-limb discrepancy in volume or circumference at point of greatest visible difference; swelling or obscuration of anatomic architecture on close inspection; pitting edema</li> <li>2: &gt;10 – 30% inter-limb discrepancy in volume or circumference at point of greatest visible difference; readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour</li> <li>3: &gt;30% inter-limb discrepancy in volume; lymphorrhea; gross deviation from normal anatomic contour; interfering with ADL</li> <li>4: Progression to malignancy (i.e., lymphangiosarcoma); amputation indicated; disabling</li> <li>5: Death</li> </ul>									
29. Edema: trunk/genital									
1: Swelling or obscuration of anatomic architecture on close inspection; pitting edema 2: Readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour 3: Lymphorrhea; interfering with ADL; gross deviation from normal anatomic contour 4: Progression to malignancy (i.e., lymphangiosarcoma); disabling 5: Death									
OTHER, NOT COVERED ABOVE	, morbidity sc	oring (	CTC v3	5.0		r			
<ul> <li><b>30. Fatigue</b></li> <li>1: Mild fatigue over baseline</li> <li>2: Moderate or causing difficulty performing</li> <li>3: Severe fatigue interfering with ADL</li> <li>4: Disabling</li> </ul>	some ADL			T					
31. Insomnia									
REMARK: If pain or other symptoms interfere v 1: Occasional difficulty sleeping, not interfer 2: Difficulty sleeping, interfering with functi 3: Frequent difficulty sleeping, interfering w 4: Disabling	ring with function on but not interfe			Grade p	rimary ev	vent(s) ca	using Insomnia		

Embrace No.	Time	72	84	96	108	120
32. Hot flashes						
1: Mild 2: Moderate						
3: Interfering with ADL						
33. Other, specify category and grad	e					
a)						
b)						
c)						
d)						
e)						
f)						

ADL: Activities of daily living. The tasks of everyday life. Basic ADLs include eating, dressing, getting into or out of a bed or chair, taking a bath or shower, and using the toilet. Instrumental activities of daily living (IADL) are activities related to independent living and include preparing meals, managing money, shopping, doing housework, and using a telephone. Also called activities of daily living.

Embrace No.		Time	72	84	96	108	120			
TUMOR STATUS										
1. Gynaecological Examination       Image: Constraint of the second										
2. Biopsy from cervix 0: Negative 1: Positive 9: Not done										
3. MRI primary tumor										
0: No tumor 1: Tumor present ( <i>If present please fill out "Follow-Up CRF</i> ") 2: Uncertain 9: MRI not performed										
4. Imaging Regional/Systemic Sta	itus	regional								
0: No nodes/mets. 1: Node/mets present ( <i>If present please</i> ) 2: Uncertainty 9: Investigations not performed	systemic <i>Up CRF</i> ")									
4a. Hydronephrosis										
0: no 1: left 2: right 3: bilat 9: NA										
<b>4b. Insufficiency Fracture</b>										
0: no 1: yes 9: NA										
4c. Other relevant findings										
Specify category:										
5. Overall Disease Status										
0: Local control 1: Persistent Disease 2: Local recurrence 9: Not evaluated	Loca	recurrence								
1: Clinical 2: Imaging 3: Biopsy	Level of c	onfirmation								
0: Regional control 1: Persistent disease 2: Regional recurrence 9: Not evaluated	Regiona	recurrence								
1: Clinical 2: Imaging 3: Biopsy	Level of c	onfirmation								
0: Systemic control 1: Systemic progression before first FUP 2: Systemic recurrence 9: Not evaluated	Systemic	recurrence								
1: Clinical 2: Imaging 3: Biopsy	Level of c	onfirmation								